Details for Patent: 12,247,012

« Back to Dashboard

Which drugs does patent 12,247,012 protect, and when does it expire?

Patent 12,247,012 protects OGSIVEO and is included in one NDA.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 12,247,012

Title:	Synthesis of nirogacestat
Abstract:	The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
Inventor(s):	Kristin Patterson, Mark Hatcher
Assignee:	SpringWorks Therapeutics Inc
Application Number:	US17/937,283
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,247,012
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 12,247,012

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-001	Nov 27, 2023		DISCN	Yes	No			Y
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-002	Apr 4, 2024		RX	Yes	No			Y
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-003	Apr 4, 2024		RX	Yes	Yes			Y

International Family Members for US Patent 12,247,012

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	126961
Australia	2022339841
Canada	3230245
Chile	2024000608